NeoGenomics, Inc.

As of August 26, 2025, NeoGenomics, Inc. shows a mildly bearish trend, with daily moving averages indicating bearish sentiment, while outperforming the S&P 500 in the short term but underperforming year-to-date.

As of February 25, 2022, NeoGenomics, Inc. is considered overvalued and risky due to negative valuation ratios and significant underperformance compared to the S&P 500.

As of February 25, 2022, NeoGenomics, Inc. is considered overvalued and has a risky valuation grade due to significant losses and poor financial metrics, including a Price to Book Value of 1.07 and an EV to EBITDA of -131.00, while underperforming the S&P 500 with a year-to-date return of -57.46%.

As of June 11, 2025, NeoGenomics, Inc. exhibits a bearish trend driven by daily moving averages, despite some mildly bullish signals on the weekly MACD and KST, while overall monthly indicators and significant underperformance against the S&P 500 reinforce the bearish outlook.

As of March 2022, the management team of NeoGenomics, Inc. includes Chairman and CEO Douglas VanOort, Lead Independent Director Lynn Tetrault, Directors Steven Jones and Rachel Stahler, and Independent Directors Bruce Crowther and Alison Hannah. They are responsible for the company's strategic direction and governance.

NeoGenomics, Inc. operates cancer-focused genetic testing laboratories and reported net sales of $168 million with a net loss of $26 million as of March 2025. The company has a market cap of $899.57 million and a debt-to-equity ratio of 0.21.

As of Jun 18, NeoGenomics, Inc. has a market capitalization of 899.57 million, with net sales of 672.35 million and a net profit of -77.58 million over the latest four quarters. Shareholder's funds are at 902.34 million, and total assets amount to 1,638.04 million.